Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Judge Matthew J"


5 mentions found


If the Supreme Court sides with the plaintiffs and decides to roll back or invalidate Food and Drug Administration regulations on mifepristone, it would be the first time the court undercut the federal agency’s authority. The abortion pill case before the Supreme Court could have implications far beyond abortion, potentially undermining the regulatory system for all medicines in the United States. If the Supreme Court sides with the plaintiffs and decides to roll back or invalidate F.D.A. They would have to pick up mifepristone in person from a doctor and would have to visit the doctor three times during the medication abortion process. and not to abortion providers, some medication abortion services have been stockpiling mifepristone and may continue prescribing and mailing their supply.
Persons: , Matthew J, mifepristone Organizations: Drug, Food and Drug Administration, Northern, Northern District of, Trump, U.S ., Appeals, Fifth Circuit Locations: United States, Northern District, Northern District of Texas
A Biden administration rule that allows employee retirement plans to consider environmental, social and governance issues in investment decisions survived a legal challenge by 26 states on Thursday. Judge Matthew J. Kacsmaryk of U.S. District Court in Amarillo, Texas, said in a 14-page opinion that he would not block the rule, part of the so-called E.S.G. investment trend that places emphasis on companies’ records on labor issues, social justice and environmental factors. Judge Kacsmaryk’s opinion found fault with the lawsuit, filed in January by Republican-led states claiming that the rule violated the federal law governing retirement plans. investing generally or ultimately agree with the rule to reach this conclusion,” Judge Kacsmaryk wrote.
Persons: Biden, Judge Matthew J, Kacsmaryk, hadn’t, ” Judge Kacsmaryk Organizations: Republican Locations: U.S, Amarillo , Texas
A federal appeals court panel said Wednesday that it would impose restrictions on the abortion pill mifepristone that would prevent the drug from being prescribed by telemedicine or dispensed through the mail. But the decision — the latest development in a closely watched lawsuit filed by abortion opponents seeking to block access to abortion pills — will not take effect until the Supreme Court ultimately decides the case. In a ruling this spring, the high court said mifepristone should remain available under the current rules until the appeals process concludes. In its ruling, a three-judge panel of the U.S. Court of Appeals for the Fifth Circuit upheld part of a decision issued in April by a federal judge in Texas. That decision, by Judge Matthew J. Kacsmaryk, had nullified the Food and Drug Administration’s approval of the pill 23 years ago.
Persons: mifepristone, Judge Matthew J, Kacsmaryk Organizations: U.S ., Appeals, Fifth Locations: Texas
Last week’s ruling by Judge Matthew J. Kacsmaryk, of the U.S. District Court for the Northern District of Texas, was a preliminary injunction saying that the F.D.A. Judge Kacsmaryk, a Trump appointee who has written critically of the Roe v. Wade decision, had stayed his order for seven days to give the F.D.A. The F.D.A had asked the appeals court to extend the stay beyond that seven days. In the decision, two Trump-appointed judges voted to reimpose some of the restrictions that the F.D.A. The third judge, appointed by President George W. Bush, said she would essentially have granted the full request.
Senior executives of more than 250 pharmaceutical and biotech companies on Monday issued a scorching condemnation of a ruling by a federal judge that invalidated the Food and Drug Administration’s 23-year-old approval of the abortion pill mifepristone, and they called for the decision to be reversed. “The decision ignores decades of scientific evidence and legal precedent,” said the letter, which was signed by leaders of some of the industry’s most prominent companies, including Albert Bourla, chief executive of Pfizer, and Alisha Alaimo, president of Biogen. The ruling, by Judge Matthew J. Kacsmaryk of the U.S. District Court for the Northern District of Texas, “has set a precedent for diminishing F.D.A.’s authority over drug approvals, and in so doing, creates uncertainty for the entire biopharma industry,” the letter argues. The letter also said that pharmaceutical companies rely on the F.D.A.’s autonomy to bring products to market under a “reliable regulatory process for drug evaluation and approval.”
Total: 5